Acute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab

R. L. Heilman, Kunam Sudhakar Reddy, M. J. Mazur, A. A. Moss, D. J. Post, S. Petrides, D. C. Mulligan

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Immunosuppression with rapid discontinuation of corticosteroids, usually with induction therapy, is safe in kidney transplant recipients. In 89 patients, we induced immunosuppression with basiliximab or rabbit antithymocyte globulin (17 and 72 patients, respectively). Selection criteria for basiliximab were age (≥65 years), history (malignancy; chronic infection), and type 1 diabetes mellitus (eligible for pancreas transplant). Steroids were administered through posttransplantation day 4 (five doses); maintenance immunosuppression was with tacrolimus and mycophenolate mofetil. At last follow-up (average, 286 days), most patients were steroid-free (antithymocyte globulin, 90%; basiliximab, 88%). Protocol biopsies were performed at 1, 4, and 12 months posttransplantation. The overall risk of biopsy-proven acute rejection was 12%. At 6 months posttransplantation, acute rejection-free survival was 93% for antithymocyte globulin, 65% for basiliximab (P < .001). Median time to biopsy-proven acute rejection was 27 and 71 days, respectively. The low incidence of biopsy-proven acute rejection with steroid-avoidance immunosuppression may be further reduced with antithymocyte globulin.

Original languageEnglish (US)
Pages (from-to)1307-1313
Number of pages7
JournalTransplantation Proceedings
Volume38
Issue number5
DOIs
StatePublished - Jun 2006

Fingerprint

Antilymphocyte Serum
Immunosuppression
Steroids
Kidney
Biopsy
Mycophenolic Acid
Tacrolimus
Type 1 Diabetes Mellitus
Patient Selection
Pancreas
Adrenal Cortex Hormones
History
Maintenance
Rabbits
Transplants
Survival
basiliximab
Transplant Recipients
Incidence
Infection

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Acute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab. / Heilman, R. L.; Reddy, Kunam Sudhakar; Mazur, M. J.; Moss, A. A.; Post, D. J.; Petrides, S.; Mulligan, D. C.

In: Transplantation Proceedings, Vol. 38, No. 5, 06.2006, p. 1307-1313.

Research output: Contribution to journalArticle

@article{57b03edf001f4baf84eb9c9d225586bc,
title = "Acute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab",
abstract = "Immunosuppression with rapid discontinuation of corticosteroids, usually with induction therapy, is safe in kidney transplant recipients. In 89 patients, we induced immunosuppression with basiliximab or rabbit antithymocyte globulin (17 and 72 patients, respectively). Selection criteria for basiliximab were age (≥65 years), history (malignancy; chronic infection), and type 1 diabetes mellitus (eligible for pancreas transplant). Steroids were administered through posttransplantation day 4 (five doses); maintenance immunosuppression was with tacrolimus and mycophenolate mofetil. At last follow-up (average, 286 days), most patients were steroid-free (antithymocyte globulin, 90{\%}; basiliximab, 88{\%}). Protocol biopsies were performed at 1, 4, and 12 months posttransplantation. The overall risk of biopsy-proven acute rejection was 12{\%}. At 6 months posttransplantation, acute rejection-free survival was 93{\%} for antithymocyte globulin, 65{\%} for basiliximab (P < .001). Median time to biopsy-proven acute rejection was 27 and 71 days, respectively. The low incidence of biopsy-proven acute rejection with steroid-avoidance immunosuppression may be further reduced with antithymocyte globulin.",
author = "Heilman, {R. L.} and Reddy, {Kunam Sudhakar} and Mazur, {M. J.} and Moss, {A. A.} and Post, {D. J.} and S. Petrides and Mulligan, {D. C.}",
year = "2006",
month = "6",
doi = "10.1016/j.transproceed.2006.02.116",
language = "English (US)",
volume = "38",
pages = "1307--1313",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Acute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab

AU - Heilman, R. L.

AU - Reddy, Kunam Sudhakar

AU - Mazur, M. J.

AU - Moss, A. A.

AU - Post, D. J.

AU - Petrides, S.

AU - Mulligan, D. C.

PY - 2006/6

Y1 - 2006/6

N2 - Immunosuppression with rapid discontinuation of corticosteroids, usually with induction therapy, is safe in kidney transplant recipients. In 89 patients, we induced immunosuppression with basiliximab or rabbit antithymocyte globulin (17 and 72 patients, respectively). Selection criteria for basiliximab were age (≥65 years), history (malignancy; chronic infection), and type 1 diabetes mellitus (eligible for pancreas transplant). Steroids were administered through posttransplantation day 4 (five doses); maintenance immunosuppression was with tacrolimus and mycophenolate mofetil. At last follow-up (average, 286 days), most patients were steroid-free (antithymocyte globulin, 90%; basiliximab, 88%). Protocol biopsies were performed at 1, 4, and 12 months posttransplantation. The overall risk of biopsy-proven acute rejection was 12%. At 6 months posttransplantation, acute rejection-free survival was 93% for antithymocyte globulin, 65% for basiliximab (P < .001). Median time to biopsy-proven acute rejection was 27 and 71 days, respectively. The low incidence of biopsy-proven acute rejection with steroid-avoidance immunosuppression may be further reduced with antithymocyte globulin.

AB - Immunosuppression with rapid discontinuation of corticosteroids, usually with induction therapy, is safe in kidney transplant recipients. In 89 patients, we induced immunosuppression with basiliximab or rabbit antithymocyte globulin (17 and 72 patients, respectively). Selection criteria for basiliximab were age (≥65 years), history (malignancy; chronic infection), and type 1 diabetes mellitus (eligible for pancreas transplant). Steroids were administered through posttransplantation day 4 (five doses); maintenance immunosuppression was with tacrolimus and mycophenolate mofetil. At last follow-up (average, 286 days), most patients were steroid-free (antithymocyte globulin, 90%; basiliximab, 88%). Protocol biopsies were performed at 1, 4, and 12 months posttransplantation. The overall risk of biopsy-proven acute rejection was 12%. At 6 months posttransplantation, acute rejection-free survival was 93% for antithymocyte globulin, 65% for basiliximab (P < .001). Median time to biopsy-proven acute rejection was 27 and 71 days, respectively. The low incidence of biopsy-proven acute rejection with steroid-avoidance immunosuppression may be further reduced with antithymocyte globulin.

UR - http://www.scopus.com/inward/record.url?scp=33745186177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745186177&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2006.02.116

DO - 10.1016/j.transproceed.2006.02.116

M3 - Article

C2 - 16797289

AN - SCOPUS:33745186177

VL - 38

SP - 1307

EP - 1313

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 5

ER -